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Abstract
Background:  Although 40–50% of non-small cell lung cancer (NSCLC) tumors respond to
cisplatin chemotherapy, there currently is no way to prospectively identify potential responders.
The purpose of this study was to determine whether transcript abundance (TA) levels of twelve
selected DNA repair or multi-drug resistance genes (LIG1, ERCC2, ERCC3, DDIT3, ABCC1, ABCC4,
ABCC5, ABCC10, GTF2H2, XPA, XPC and XRCC1) were associated with cisplatin chemoresistance
and could therefore contribute to the development of a predictive marker. Standardized RT
(StaRT)-PCR, was employed to assess these genes in a set of NSCLC cell lines with a previously
published range of sensitivity to cisplatin. Data were obtained in the form of target gene molecules
relative to 106 β -actin (ACTB) molecules. To cancel the effect of ACTB variation among the different
cell lines individual gene expression values were incorporated into ratios of one gene to another.
Each two-gene ratio was compared as a single variable to chemoresistance for each of eight NSCLC
cell lines using multiple regression. In an effort to validate these results, six additional lines then
were evaluated.
Results: Following validation, single variable models best correlated with chemoresistance (p <
0.001), were ERCC2/XPC, ABCC5/GTF2H2, ERCC2/GTF2H2, XPA/XPC and XRCC1/XPC. All single
variable models were examined hierarchically to achieve two variable models. The two variable
model with the highest correlation was (ABCC5/GTF2H2, ERCC2/GTF2H2) with an R2 value of 0.96
(p < 0.001).
Conclusion: These results provide markers suitable for assessment of small fine needle aspirate
biopsies in an effort to prospectively identify cisplatin resistant tumors.
Background
Non-small cell lung cancer (NSCLC) is the most common
type of bronchogenic carcinoma. Although chemothera-
peutic regimens with greater efficacy continue to be devel-
oped, the best regimens presently give an overall response
rate of only 30–50%. Lack of response is attributable to
resistance that is present de novo or develops in response
to treatment. If the resistance to drugs could be
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surmounted or if the most effective drug candidates for
treatment could be better determined, the impact in terms
of survival would be substantial. Because mechanisms of
chemoresistance likely involve multiple gene products,
we hypothesize that patterns of individual gene expres-
sion and/or indices comprising the expression values of
multiple genes will provide more effective markers of
chemoresistant NSCLC tumors than values of individual
genes.
Currently, cisplatin and carboplatin are among the most
widely used cytotoxic anticancer drugs. However, resist-
ance to these drugs through de novo or induced mecha-
nisms undermines their curative potential [1]. Recently,
understanding regarding potential modes of chemoresist-
ance to platinum compounds has been obtained through
studies correlating cytotoxicity with nucleotide excision-
repair (NER) [2-7] or drug uptake/efflux [7-13]. In this
study, we investigated whether de novo gene expression
differences are correlated with a predisposition of NSCLC
tumors to chemoresistance.
Current advances in technology, including microarrays
and quantitative RT-PCR methods, enable classification of
cancer types on the basis of TA levels rather than histo-
morphology [14,15]. For example, these techniques ena-
ble the discovery of predictive markers based on TA
profiles. Microarray screening analysis currently is being
investigated to predict chemotherapeutic sensitivity based
on TA profiles [16-18]. An advantage of microarray analy-
sis is that thousands of genes may be simultaneously eval-
uated. However, it is generally recognized that, due to lack
of standardization, relatively low sensitivity and relatively
poor lower thresholds of detection, microarray assess-
ments need to be confirmed with follow-up quantitative
methods. StaRT-PCR is a method that enables rapid, sen-
sitive, reproducible, standardized, quantitative measure-
ments for many genes simultaneously [19,49,50].
Briefly, in StaRT-PCR, the TA level of each gene is made
relative to an internal standard (IS) within a standardized
mixture of internal standards (SMIS). Known concentra-
tions of these mixtures are combined with cDNA samples
in a master mixture for PCR amplification. This enables
quantitative measurement of gene expression while con-
trolling for inter-sample, inter-experimental and loading
differences. With StaRT-PCR, due to the presence of the
SMIS, the measurements are quantitative and quality-con-
trolled when measured either kinetically or at endpoint
[51,52]. In other words, measurement of each TA value
relative to a known quantity of internal standard controls
for variation in amplification efficiency in early, log-lin-
ear, and plateau phases of PCR [53].
In an initial survey, StaRT-PCR was used to measure
expression of 35 genes involved in DNA repair, multi-
drug resistance, cell cycling and apoptosis in two cell lines
previously reported to be the least (H460) and most
(H1435) chemoresistant among 20 NSCLC cell lines [20].
It was determined that genes involved in DNA repair
(ERCC2, XRCC1) and drug influx/efflux (ABCC5) were
associated with chemoresistance. The number of genes
from each of these two categories was expanded to include
additional representative genes associated with general-
ized DNA damage recognition and repair (DDIT3), asso-
ciated specifically with NER (LIG1, ERCC3, GTF2H2, XPA,
XPC), or associated with drug transport (ABCC1, ABCC4,
ABCC10). Expression of these twelve genes was measured
in eight NSCLC cell lines with variable cisplatin resistance
[20]. StaRT-PCR data were obtained using ACTB as a ref-
erence gene. Thus, data were reported in the form of
mRNA molecules/106 ACTB molecules. These data then
were combined into interactive transcript abundance
indices (ITAI) by placing one or more genes directly asso-
ciated with the phenotype on the numerator and one or
more genes negatively associated with the phenotype on
the denominator [19,21]. It is reasonable to expect that
optimal predictors of phenotypes are more likely to be
discovered among ITAI than among expression levels of
individual genes. This has been demonstrated for certain
cancer-related phenotypes [19,21-23]. A further advan-
tage of ITAI is that they control for previously observed
variation in the reference gene value (in this case, ACTB)
from one cell line to another [19,21]. When a single gene
in the numerator is divided by another single gene in the
denominator, the reference value mathematically cancels
out. The ITAI values were compared to cisplatin chemore-
sistance among the eight NSCLC cell lines with variable
resistance. Results then were validated in an additional six
NSCLC cell lines.
Results
Reproducibility
Among the gene expression measurements for which
three or more replicate values were obtained, the mean
coefficient of variation was 38.5% (see Additional file 1).
This is similar to the reproducibility observed in other
gene expression studies using the StaRT-PCR method
[19,22]. Recently, through implementation of robotic liq-
uid handlers, automation software, and standard operat-
ing procedures in the NCI funded (CA95806)
Standardized Expression Measurement (SEM) Center, var-
iation among replicates has been reduced to a CV of less
than 10% [50].
Individual gene expression measurements and 
chemoresistance
The results of the direct comparison of individual gene
expression mean values versus cisplatin chemoresistanceMolecular Cancer 2005, 4:18 http://www.molecular-cancer.com/content/4/1/18
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are presented in Table 1. All StaRT-PCR data values were
in the form of molecules/106 ACTB molecules (see Addi-
tional file 1). For 8/12 genes assessed, the correlation was
significant (p < 0.05).
Establishment of inter-active transcript abundance indices
ITAI were established as balanced ratios comprising every
possible combination with one gene divided by the TA
value of another gene for data obtained from each of the
initial eight NSCLC cell lines (Group 1). Each TA value
was calculated as molecules/106 ACTB molecules. Thus, in
these ITAI, the effect of the reference gene, ACTB, is can-
celled. For example: ERCC2 molecules/106 ACTB mole-
cules ÷ XPC  molecules/106 ACTB  molecules = ERCC2
molecules/XPC molecules. Bivariate analysis of each two-
gene ratio versus corresponding cisplatin IC50 chemore-
sistance value was conducted among the eight cell lines
(see Additional file 2). There were 12 genes assessed and
11 sets of ratios for each gene as the numerator resulting
in 132 ratios. The data from bivariate analyses then were
ranked in descending order such that the ratio set listed
first was that for which the mean value for correlation
with chemoresistance was highest, and the ratio set listed
last was that for which the mean r value for correlation
with chemoresistance was lowest. Thus, the ratio set with
ERCC2 in the numerator is listed first because the mean r
value for the ratios between ERCC2 and each of the other
eleven genes was the most positive among the twelve
genes evaluated. In contrast, the ratio set with XPC in the
numerator is listed last because the ratios between XPC
and each of the other 11 genes had the most negative cor-
relation with chemoresistance.
Modelling of gene expression with chemoresistance
The ratios ERCC2/XPC, ABCC5/GTF2H2, ERCC2/XRCC1,
ERCC2/GTF2H2, XPA/XPC, XRCC1/XPC, and ABCC5/XPC
were the best (i.e. those single variable models with high-
est R2 identified in the initial eight NSCLC cell lines by
simple linear regression (see Additional file 2). The effect
of adding a second variable into the model was then
assessed. The best two variable model was (ABCC5/
GTF2H2, ERCC2/GTF2H2) with an R2 value of 0.96.
Validation of Models
We tested our single and two variable models in an addi-
tional six NSCLC cell lines (Table 2). In statistical analysis
of the combined data for all 14 NSCLC cell lines, the p
value improved or stayed the same for three of the single
variable models (ERCC2/XPC, ABCC5/GTF2H2, XRCC1/
XPC), as well as the two variable model. The decline in p
value for ERCC2/GTF2H2 and XPA/XPC was not signifi-
cant. In contrast, ERCC2/XRCC1 was no longer signifi-
cantly associated with chemoresistance, and the p value
declined substantially for ABCC5/XPC.
Discussion
The results obtained by measuring gene expression with
StaRT-PCR, incorporating values for individual genes into
ITAI, and correlating ITAI with chemoresistance led us to
propose several models as potential predictors of cisplatin
Table 1: Correlation between each of twelve putative chemoresistance transcript abundance values and chemoresistance among 
NSCLC cell lines. Eight of the 12 selected multi-drug resistance and DNA repair genes were significantly correlated with 
chemoresistance among the first group of 8 NSCLC cell lines evaluated (Group 1). In order to validate these results, an additional six 
lines were evaluated (Group 2).
Group 1a Groups 1 and 2b
Gene R2 p value R2 p value
ABCC5 0.93 0.0001 0.85 0.0001
ERCC2 0.85 0.0012 0.82 0.0001
XPA 0.81 0.0023 0.75 0.0001
LIG1 0.78 0.0034 NAc NA
DDIT3 0.68 0.0120 NA NA
ABCC1 0.64 0.0164 NA NA
XRCC1 0.56 0.0318 0.57 0.0019
ERCC3 0.56 0.0319 NA NA
ABCC4 0.37 0.1081 NA NA
ABCC10 0.06 0.5641 NA NA
GTF2H2 0.02 0.7424 0.04 0.5183
XPC 0.00 0.9851 0.02 0.6654
a Initial 8 NSCLC cell lines analyzed. b All 14 NSCLC cell lines analyzed. cNot Assessed.Molecular Cancer 2005, 4:18 http://www.molecular-cancer.com/content/4/1/18
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chemoresistance in cultured NSCLC cells. These models
comprise genes that have been associated with cisplatin
chemoresistance in previous studies including ABCC5
[13], and XPA [4,24].
Experimental results suggest that increased expression of
ABCC5, also known as MRP5, is associated with exposure
to platinum drugs in lung cancer in vivo and/or the
chronic stress response to xenobiotics [13]. Thus,
increased resistance to platinum drugs with increased
ABCC5 levels may be due to glutathione S-platinum com-
plex efflux. Increased efflux of platinum drugs could result
in lower levels of drug available to form damaging DNA-
platinum drug adducts.
XPA and ERCC2 are components of the nucleotide exci-
sion repair (NER) mechanism, which generally is recog-
nized as the major repair response to DNA damage
induced by chemotherapeutic agents such as cisplatin
[1,3,7]. In NER, XPA is the main DNA lesion recognition
protein [25], is the key element in assembly of the NER
complex by recruiting several other proteins to the lesion
site [26] and XPA levels are rate-limiting for NER [4,27].
Enhanced NER gene expression is a major cause of resist-
ance to cisplatin and other DNA-damaging chemothera-
peutic agents [3,28] and over expression of the XPA gene
component of NER has been associated with resistance to
cisplatin in human ovarian cancer [4,24]. ERCC2 specifi-
cally is a component of the transcription factor IIH
(TFIIH) that consists of seven polypeptides [29,30] and in
its entirety is a repair factor [31-33]. In NER, ERCC2 (or
XPD) is essential for TFIIH helicase activity [34] and it has
been demonstrated more recently that ERCC2 interacts
specifically with GTF2H2 (or p44) and that this interac-
tion results in the stimulation of the 5' to 3' helicase activ-
ity [35]. In at least some other tissues, ERCC1 is associated
with cisplatin resistance, while ERCC2  is not [36,37].
Thus, our data support the importance of excision repair
in cisplatin resistance, but suggest that there is inter-tissue
variation in the excision repair genes that are responsible
for de novo cisplatin resistance.
XRCC1 has long been recognized as a key component of
the base excision repair (BER) pathway, acting as a "scaf-
fold" for the coordination of other BER proteins at the
sites of base damage during repair [38-40]. It has been
shown that polymorphisms in XRCC1, while in them-
selves are not associated with increased risk of lung can-
cer, have shown an increased risk of lung cancer in a
supermultiplicative manner when associated with poly-
morphisms in another component of BER, poly (ADP-
ribose) polymerase family, member 1 transfersase
(PARP1) [41]. XRCC1 has also recently been proposed as
a component of an alternative nonhomologous end-join-
ing route of DNA double-stranded breaks (DSBs), that
complements the predominant repair pathway of DNA-
dependent protein kinase (DNA-PK) and X-ray repair
complementing defective repair in Chinese hamster cells
4 (XRCC4)-DNA ligase IV complex [42]. Although the
NER pathway is the major repair mechanism for cisplatin-
DNA adducts, our data supports the proposal of overlap-
ping repair pathways involved in alternative repair of
Table 2: Bivariate correlation between two-transcript abundance ratios and chemoresistance in a validation set of NSCLC cell lines. 
The ratios best correlated with chemoresistance from Additional file 2 were evaluated in an additional six lines. The effect of adding a 
second variable into the model was assessed. ERCC2/XPC was no longer correlated with chemoresistance and ABCC5/XPC had 
substantially lower p value. The other single variable models and the two variable model were validated.
Model Group 1a Groups 1 and 2b
Single variable Model r2 p value Model r2 p value
ERCC2/XPC 0.91 0.0002 0.69 0.0002
ABCC5/GTF2H2 0.91 0.0002 0.88 0.0001
ERCC2/XRCC1 0.90 0.0003 NSc
ERCC2/GTF2H2 0.90 0.0004 0.63 0.0007
XPA/XPC 0.89 0.0004 0.62 0.0008
XRCC1/XPC 0.88 0.0005 0.75 0.0001
ABCC5/XPC 0.88 0.0006 0.29 0.0461
Two variable Model r2 p value Model r2 p value
ABCC5/GTF2H2 and 
ERCC2/GTF2H2
0.96 0.0003 0.91 0.0001
a Initial 8 NSCLC cell lines analyzed. b All 14 NSCLC cell lines analyzed. cnot significant (p > 0.05).Molecular Cancer 2005, 4:18 http://www.molecular-cancer.com/content/4/1/18
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cisplatin adducts, such as the BER pathway. XRCC1 may
also be involved in the repair of other types of DNA dam-
age caused by cisplatin including DSBs.
Selection of a stable reference for the amount of sample
loaded for each gene expression measurement is impor-
tant to ensure measurement accuracy and reproducibility.
With microarray analysis, because thousands of genes are
assessed simultaneously, an index of all genes measured
provides a stable reference for the amount of sample
loaded from one microarray to another. In quantitative
RT-PCR studies, typically, a single non-regulated gene is
used as a loading reference, such as ACTB, GAPD, cyclo-
philin or ribosomal RNA. However, all of these genes have
been reported to vary among multiple samples. One way
to assess inter-sample variation in reference gene expres-
sion among multiple samples is to compare variation
between two reference genes. In our experience, ACTB and
GAPD vary 50-fold relative to each other among bronchial
epithelial cells (BEC) and even more between BEC and
other cell types [19,44]. In situations where limited num-
bers of genes are measured (< 200), an index of all genes
for the normalization of data is not sufficiently stable. In
order to eliminate the effect of unknown variation in the
reference gene expression among samples, we analyzed
balanced ratios of one gene expression value obtained by
StaRT-PCR to another. These balanced ratios did not rep-
resent actual cellular concentration changes of the indi-
vidual genes comprising the ratio, but related the
expression of one gene to another and could be used for
comparison with phenotypic determinants such as chem-
oresistance. In this study, ITAI analysis (Table 2) con-
firmed most of the results obtained by analysis of
individual gene expression values relative to chemoresist-
ance (Table 1). This suggests that variation in ACTB
among this group of cDNA samples was not significant.
However, in our experience inter-sample variation in
ACTB expression is greater among primary samples. Thus,
we will continue to use ITAI to remove doubt regarding
potential effect of variation in reference gene expression
whenever possible.
As is presented in Table 2, by evaluating an empirically
derived set of balanced ratios (ITAI) derived from expres-
sion values for all of the genes measured, it is possible to
establish a hierarchy regarding the strength of association
between a set of genes and a phenotype.
Conclusion
In summary, the association of ERCC2, ABCC5, XPA, and
XRCC1 with chemoresistance was established through a
sequential process involving a) screening genes represent-
ing many different functional classes, b) evaluating an
expanded group of genes represented by those that were
positively associated in the first round, c) identification of
outliers (see Additional file 2), d) model building and e)
validation (Table 2). Although only two of the 35 genes
assessed in the first round were correlated with chemore-
sistance, 8/12 of the selected DNA repair and MDR genes
were correlated. The models established in this study
demonstrate the importance of evaluating the interaction
among multiple genes representing multiple pathways
involved in cisplatin chemoresistance. These models will
be tested through a blinded study of gene expression lev-
els of the identified potential markers in samples consist-
ing of fine needle aspirate (FNA) biopsies from patients
with various treatment outcomes.
Methods
Cell culture
Non-small cell lung cancer (NSCLC) cell lines with vary-
ing levels of cisplatin chemoresistance, H460, H1155,
H23, H838, H1334, H1437, H1355, H1435, H358,
H322, H441, H522, H226 and H647, were obtained from
the American Type Culture Collection (Rockville, MD).
The previously reported [20] cisplatin IC50 concentration
for each line is provided in Table 3. All cells were incu-
bated in RPMI-1640 medium (Biofluids, Inc., Rockville,
MD) containing 10% fetal bovine serum (FBS) and 1 mM
glutamine at 37°C in the presence of 5% CO2. Prolifera-
tive, subconfluent cultures were obtained for RNA
extractions and subsequent analyses.
Reagents
10X PCR buffer for the Rapidcycler (500 mM Tris, pH 8.3;
2.5 mg/µl BSA; 30 mM MgCl2) was obtained from Idaho
Table 3: Cisplatin chemoresistance in 14 non-small cell cancer 
cell lines
NSCLC cell line Cisplatin IC50 (µM)
Group 1b NCI-H460 0.52 ± 0.04
NCI-H1155 0.90 ± 0.20
NCI-H23 2.09 ± 0.32
NCI-H838 3.86 ± 0.31
NCI-H1334 5.15 ± 0.47
NCI-H1437 5.90 ± 1.61
NCI-H1355 6.74 ± 1.29
NCI-H1435 22.86 ± 2.36
Group 2c NCI-H358 1.16 ± 0.24
NCI-H322 2.85 ± 0.22
NCI-H441 3.38 ± 0.99
NCI-H522 3.53 ± 0.56
NCI-H226 5.05 ± 0.95
NCI-H647 7.27 ± 1.14
a Previously published results by Chun-Ming Tsai, et.al. [20]
b Initial set of 8 NSCLC cell lines evaluated.
c Additional set of 6 NSCLC cell lines evaluated.Molecular Cancer 2005, 4:18 http://www.molecular-cancer.com/content/4/1/18
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Technology, Inc. (Idaho Falls, ID). Taq polymerase (5 U/
µl), oligo dT primers, RNasin (25 U/µl) and dNTPs were
obtained from Promega (Madison, WI). M-MLV reverse
transcriptase (200 U/µl) and 5X first strand buffer (250
mM Tris-HCl, pH 8.3; 375 mM KCl; 15 mM MgCl2; 50
mM DTT) were obtained from Gibco BRL (Gaithersburg,
MD). DNA 7500 Assay kits containing dye, matrix and
standards were obtained from Agilent Technologies, Inc.
(Palo Alto, CA). All other chemicals and reagents were
molecular biology grade.
RNA extraction and reverse transcription
Total RNA was isolated from cell cultures by a TriReagent
protocol (Molecular Research Center, Inc., Cincinnati,
OH) [43]. Following extraction, approximately 1 µg of
total RNA for each cell line was reverse-transcribed using
M-MLV reverse-transcriptase and an oligo dT primer as
previously described [44].
Quantitative standardized RT (StaRT)-PCR
Gene expression was determined using previously pub-
lished quantitative StaRT-PCR protocols [19,44-50].
Briefly, a master mixture containing buffer, MgCl2, dNTPs,
sample cDNA, Taq polymerase and SMIS was prepared
and 9 µl aliquots dispensed into 0.6 ml microfuge tubes
containing 1 µl of gene-specific primers. A SMIS com-
prises gene-specific IS's for each gene at defined concen-
trations relative to one another. The mixture includes IS's
for reference (or housekeeping genes) to control for cDNA
loading and to simplify normalization of all gene data. All
primers used for PCR and those used in the construction
of the CTs, are listed in Additional file 3. PCR reactions
mixtures were subjected to 35 cycles of PCR with 5 sec-
onds of denaturation at 94°C, 10 seconds of annealing at
58°C and 15 seconds of elongation at 72°C in a Rapidcy-
cler (Idaho Technology, Inc.). PCR products were electro-
phoretically separated and quantified in an Agilent 2100
Bioanalyzer (Agilent Technologies, Inc.) with the DNA
7500 Assay kit. The area under the curve (as calculated by
Agilent software) for each native template (NT) and IS
peak was used in all calculations. Representative electro-
pherograms of each gene assessed are presented in Addi-
tional file 4. The NT/IS ratio for a reference gene, ACTB,
and the NT/IS ratios for each target gene were calculated.
The initial number of NT molecules for each gene then
could be determined from these ratios because the initial
number of IS molecules added into the PCR reaction was
known. To normalize measurements and control for sam-
ple-to-sample variation and inter-experimental loading,
the calculated number of target gene molecules was
divided by the calculated number of ACTB molecules. A
size correction was employed to correct for fluorescence
intensity differences affecting the measured area under the
curve [19,48].
Statistical analyses
Ratios of one gene to another, from each of the initial
eight NSCLC cell lines, were subjected to multiple regres-
sion analysis using SAS 6.12 (SAS Institute Inc., Cary, NC)
to determine the combination of genes that best predict
cisplatin resistance. Each ratio was compared separately to
chemoresistance and ratios with significant correlation to
resistance (R2 ≥  0.88, p < 0.001) then were examined hier-
archically to achieve two variable models based on the
highest R2 values. Following assessment of an additional
6 cell lines, results for all 14 NSCLC cell lines were com-
bined and also subjected to analysis as described.
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